Trial Profile
Randomized, double-blind, placebo-controlled study of AMG0001(HGF plasmid) for patients with arteriosclerosis obliterans
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Arteriosclerosis obliterans; Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors AnGes
- 04 Jun 2007 New trial record.